Drug Trial Radar · NCT05016661
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
466
Actual
Start
Oct 19, 2021
Primary completion
Jul 31, 2024
Study completion Aug 30, 2024
Sponsor
- Lead sponsor
- AEON Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll approximately 666 patients across approximately 65 sites in the United States, Canada and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of ABP-450 utilizing the Company's novel injection paradigm.
Conditions
- Migraine
Interventions
ABP-450Drug
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse EventsTime frame: Baseline to Week 52 - End of Study
- Change in Monthly Migraine DaysTime frame: Baseline to Week 52 - End of Treatment Period
Locations
55 sites in 3 countries. Site status is shown where the registry gives one.
MDFirst Research
Chandler, Arizona
Elite Clinical Studies, LLC
Phoenix, Arizona
Arizona Neuroscience Research
Phoenix, Arizona
Clinical Research Consortium Arizona
Tempe, Arizona
Axiom Research LLC
Colton, California
Velocity Research San Diego
La Mesa, California
Los Angeles Headache Center
Los Angeles, California
Anderson Clinical Research
Redlands, California
Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS
San Diego, California
Delta Waves LLC - Hunt - PPDS
Colorado Springs, Colorado
Paradigm Clinical Research Centers
Wheat Ridge, Colorado
New England Institute for Neurology and Headache
Stamford, Connecticut
Quality Research of South Florida
Hialeah, Florida
Sandhill Research, LLC
Lake Mary, Florida
Canvas Clinical Research
Lake Worth, Florida
BioMed Research Institute, INC
Miami, Florida
Renstar Medical Research
Ocala, Florida
Innovation Medical Research Center
Palmetto Bay, Florida
Clinical Research of Central Florida - ClinEdge - PPDS
Winter Haven, Florida
NeuroTrials Research Inc. - Clinedge - PPDS
Atlanta, Georgia
Drug Studies America, Inc
Marietta, Georgia
Velocity Clinical Research - Boise - ERN - PPDS
Meridian, Idaho
Cedar Crosse Research Center
Chicago, Illinois
Kansas Institute of Research, LLC
Overland Park, Kansas
Crescent City Headache and Neurology Center
Chalmette, Louisiana
Legacy Clinical Solutions: Tandem Clinical Research, LLC - Clinedge - PPDS
Marrero, Louisiana
Boston Clinical Trials Inc
Boston, Massachusetts
MedVadis Research
Waltham, Massachusetts
Quest Research Institute - Hunt - PPDS
Farmington Hills, Michigan
StudyMetrix Research, LLC
City of Saint Peters, Missouri
Clinvest Research LLC
Springfield, Missouri
Barrett Clinic, P.C. - Clinedge - PPDS
La Vista, Nebraska
Quality Clinical Research
Omaha, Nebraska
Wake Research - CRCN, LLC
Las Vegas, Nevada
Albuquerque Clinical Trials Inc - Clinedge - PPDS
Albuquerque, New Mexico
Dent Neurologic Institute
Amherst, New York
Upstate Clinical Research Associates LLC
Williamsville, New York
META Medical Research Institute, LLC
Dayton, Ohio
Centricity Research Dublin Multispecialty
Dublin, Ohio
The Orthopedic Foundation
New Albany, Ohio
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.